SCHOTT Pharma Invests €100 Million to Expand RTU Sterile Cartridge Production Capacity

SCHOTT Pharma has confirmed a €100 million ($114 million) investment aimed at increasing its production capacity for ready-to-use (RTU) sterile cartridges. The company plans to expand its manufacturing capabilities to meet growing demand in the pharmaceutical sector, particularly for pre-filled drug delivery systems.

The investment will focus on enhancing facilities dedicated to RTU cartridges, which are widely used for injectable medications. These cartridges are designed to simplify the drug administration process while maintaining sterility and safety standards. SCHOTT Pharma’s decision reflects industry trends favoring pre-filled solutions that improve efficiency and reduce contamination risks during medical procedures.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 6, 2025

Related posts:

Drug Patent Searching: USPTO and EPO Databases Aid Pharmaceutical Professionals in Competitive Analysis. Music-Induced “Chills” Trigger Natural Opioids in the Brain Affordable Supplement Linked to Potential Heart Failure Prevention in Type 2 Diabetes Patients Gradual Reduction of Benzodiazepines Essential to Prevent Life-Threatening Withdrawal Symptoms

Author

Mark Chiang